Objectives
The goal of this study is to clarify the inflammatory elements that cause Lung Cancer and Chronic Obstructive Pulmonary Disease (LC-COPD) to interfere with thyroid activity. Furthermore, pinpoint phenotypes at high risk and examine if alterable mediators facilitate focused prevention and control of LC-COPD and its widespread effects.
Key Research Questions:
1. What genetic variations are associated with LC-COPD?
2. How does LC-COPD disrupt thyroid function through inflammatory factors?
3. Which high-risk patient profiles possess modifiable inflammatory or endocrine mediators that can be leveraged for early detection, prevention, and integrated management of LC-COPD and its systemic sequelae?
The study’s objective is to provide a comprehensive understanding of the interplay between these factors, contributing to improved prevention and management strategies for LC-COPD and their Thyroid function.
Scientific Rationale
Chronic respiratory diseases, notably COPD and lung cancer, create a significant worldwide health challenge. In COPD sufferers, especially older smokers, lung cancer often coexists, leading to Lung Cancer and Chronic Obstructive Pulmonary Disease (LC-COPD) syndrome where each ailment intensifies the other’s risk and complexity. LC-COPD’s chronic inflammation extends beyond the lungs, with inflammatory agents spreading through the bloodstream, impacting organs beyond the lungs, such as the thyroid. The ensuing endocrine malfunction intensifies symptoms, escalates the need for hospital stays, and raises death rates, but the exact processes connecting LC-COPD with thyroid irregularities are still not well understood. The effectiveness of specific treatments for thyroid issues in LC-COPD remains a topic of debate, highlighting the critical importance of identifying changeable agents and high-risk traits for accurate prevention, early identification, and comprehensive treatment of LC-COPD, and their widespread consequences.